|
Roquefort Therapeutics PLC on Monday said it entered into heads of terms to buy Coiled Therapeutics Inc, also known as Coiled USA, via a reverse takeover. The London-based biotechnology company, which focuses on developing medicines in the immunology and oncology sectors, said it plans to pay £30 million upfront, payable in shares. Roquefort said Coiled USA is a spin-out from A2A Pharmaceuticals, which holds exclusive worldwide rights to AO-252: a novel first-in-class first-in-human new drug alternative targeting the TACC3 protein to treat cancer. It added that AO-252 is currently in a phase 1 trial in the US in advanced solid tumours and is showing ‘encouraging’ efficacy, responses and clinical benefit with a very benign safety profile. Roquefort said: ‘AO-252 has shown strong preclinical efficacy with complete tumour regression as monotherapy in ovarian, triple negative breast, endometrial, gastric, and prostate cancers with strong efficacy in in-vivo brain metastases as well.’ Roquefort Executive Chair Stephen West said: ‘We believe this is a fantastic opportunity to pivot Roquefort Therapeutics from being a pre-clinical company into a clinical stage company creating a clear path to value inflection.’ Upon completion of the planned reverse takeover, Roquefort’s shares on London’s Main Market will be cancelled. Coiled USA Chief Executive Officer Sridhar Vempati said: ‘Merging Coiled USA into Roquefort Therapeutics marks a major step for our company. In addition to progressing the clinical development of AO-252, Roquefort’s Therapeutics’ STAT-6 program is a promising addition to our pipeline. ‘We believe that AO-252 is a novel and potentially transformative treatment across multiple cancer indications.’ Roquefort shares jumped 42% to 2.35 pence each on Monday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
